SEC 13F Intelligence

Managers / Q4 2021 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$126M
Q4 2021
Positions
69
Filings on Record
30
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Highvista Strategies LLC reported $126M in U.S.-listed holdings across 69 positions for Q4 2021.

Its largest position, DELL, represents 15.9% of the portfolio.

Compared with Q3 2021, the fund opened 16 new positions and exited 74.

Portfolio Metrics

Turnover
+25.3%
vs prior filed quarter
Top-10 Concentration
+47.5%
share of reported value
Largest Position
+15.9%
Dell Technologies
New / Exited
16 / 74
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 78.7%Other: 15.7%REIT: 2.8%ADR: 2.1%ETP: 0.7%
  • Common Stock · 78.7% · $99M
  • Other · 15.7% · $20M
  • REIT · 2.8% · $3M
  • ADR · 2.1% · $3M
  • ETP · 0.7% · $881,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
COHREURCOHERENT INCNEW+13.6K13.6K+$4M$4M
PBCTEURPEOPLES UNITED FINANCIAL INCNEW+196.1K196.1K+$3M$3M
CONE1EURCYRUSONE INCNEW+38.7K38.7K+$3M$3M
MERUS N VNEW+53.8K53.8K+$2M$2M
CYTKCYTOKINETICS INCNEW+35.2K35.2K+$2M$2M
2662247DITEOS THERAPEUTICS INCNEW+34.5K34.5K+$2M$2M
FULCFULCRUM THERAPEUTICS INCNEW+90.0K90.0K+$2M$2M
CRNXCRINETICS PHARMACEUTICALS INNEW+53.0K53.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C15.89%$20M355.4K
2CPNGCOUPANG INChistory →CL A5.99%$8M256.3K
3XLNXEURXILINX INChistory →COM4.08%$5M24.2K
4MSD ACQUISITION CORPUNIT 03/25/20264.04%$5M500.0K
5IHS MARKIT LTDSHS3.46%$4M32.7K
6COHREURCOHERENT INChistory →COM2.89%$4M13.6K
7NUANEURNUANCE COMMUNICATIONS INChistory →COM2.86%$4M64.8K
8PBCTEURPEOPLES UNITED FINANCIAL INChistory →COM2.78%$3M196.1K
9CONE1EURCYRUSONE INChistory →COM2.76%$3M38.7K
10CHNGUSDCHANGE HEALTHCARE INChistory →COM2.76%$3M162.1K
11CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.59%$2M200.0K
12ARNAEURARENA PHARMACEUTICALS INChistory →COM NEW1.59%$2M21.4K
13XENEXENON PHARMACEUTICALS INChistory →COM1.56%$2M62.9K
14ARGXARGENX SEhistory →SPONSORED ADR1.55%$2M5.6K
15MERUS N VCOM1.36%$2M53.8K
16OPHTEURIVERIC BIO INChistory →COM1.35%$2M101.1K
17TVTXTRAVERE THERAPEUTICS INChistory →COM1.34%$2M54.1K
18ACRSACLARIS THERAPEUTICS INChistory →COM1.30%$2M112.2K
19CYTKCYTOKINETICS INChistory →COM NEW1.28%$2M35.2K
202662247DITEOS THERAPEUTICS INChistory →COM1.28%$2M34.5K
21FULCFULCRUM THERAPEUTICS INChistory →COM1.27%$2M90.0K
22CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.20%$2M53.0K
232655787DBLUEPRINT MEDICINES CORPhistory →COM1.18%$1M13.8K
242JQGRITSTONE BIO INChistory →COM1.16%$1M113.8K
25RLAYRELAY THERAPEUTICS INChistory →COM1.12%$1M46.0K
26PROTHENA CORP PLCSHS1.10%$1M28.1K
27MRTXEURMIRATI THERAPEUTICS INChistory →COM1.08%$1M9.2K
28UTHUNITED THERAPEUTICS CORP DELhistory →COM1.08%$1M6.3K
29FATEFATE THERAPEUTICS INChistory →COM1.07%$1M23.1K
30AM6AMICUS THERAPEUTICS INChistory →COM1.04%$1M113.4K
31IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.01%$1M66.6K
32HORIZON THERAPEUTICS PUB LSHS0.97%$1M11.3K
33ALNYALNYLAM PHARMACEUTICALS INCCOM0.96%$1M7.1K
34TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.92%$1M29.9K
35KURAKURA ONCOLOGY INCCOM0.92%$1M82.1K
36ASCENDIS PHARMA A/SSPONSORED ADR0.91%$1M8.5K
37VRTXVERTEX PHARMACEUTICALS INCCOM0.90%$1M5.1K
38MORFUSDMORPHIC HLDG INCCOM0.90%$1M23.8K
39VTGNUSDVISTAGEN THERAPEUTICS INCCOM NEW0.90%$1M577.0K
40SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.88%$1M17.9K
41BEAMBEAM THERAPEUTICS INCCOM0.86%$1M13.5K
42PTGXPROTAGONIST THERAPEUTICS INCCOM0.84%$1M31.0K
43RNAGBPAVIDITY BIOSCIENCES INCCOM0.84%$1M44.3K
44NTRANATERA INCCOM0.82%$1M11.0K
45RCKTROCKET PHARMACEUTICALS INCCOM0.82%$1M46.9K
46CCCCC4 THERAPEUTICS INCCOM STK0.81%$1M31.5K
47WHWKAADI BIOSCIENCE INCCOM0.78%$979,00040.5K
48INSTIL BIO INCCOM0.78%$974,00056.9K
49RGNXREGENXBIO INCCOM0.77%$973,00029.8K
50IDYAIDEAYA BIOSCIENCES INCCOM0.76%$960,00040.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.